/Investor DB

Pureos Bioventures — 2022 Investments

5 investments dated 2022 · listed companies and verified rows first · show all

Araris Biotechararisbiotech.comSeries A · Oct 2022 · $24M✓ verified

Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy.

BiotechMedical DevicesBasel, CH

Dragan Grabulovski(Co-founder and CEO)inPhilipp Spycher(Co-founder and Chief Scientific Officer)inIsabella Attinger-Toller(Co-founder)in

Co-investorsVI PartnersredalpineSamsung Venturesb2ventureKinled Holding4BIO Capital

Engimmune Therapeuticsengimmune.cominSeed · May 2022 · $16M✓ verified

Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications.

AI & Machine LearningBiotechDeep Tech

Rodrigo Vazquez-LombardiinSai Reddyin

Co-investorsNovo Holdings

MinervaXminervax.cominSeries C · Dec 2022 · $23M✓ verified

MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.

BiotechHealthtech

PerBengt(CSO)

Co-investorsAdjuvant CapitalIndustrifondenOrbiMedSanofi VenturesSunstone CapitalEQT Life Sciences+2 more

Tridek Onetridekone.cominSep 2022 · $16M✓ verified

Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.

BiotechDeep TechHealthtechParis, FR

Co-investorsAdvent Life SciencesBioqube VenturesBpifranceAdBio partners

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Ariceum Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.